Skip to main content
SpringerLink
Log in

24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas

  • Original Contributions
  • Published:
Acta diabetologia latina Aims and scope Submit manuscript

Summary

Based on the known action of xanthine derivatives on the insulin secretion, the effect of pentoxifylline on carbohydrate homeostasis of type I (IDDM) and type II (NIDDM) diabetics was investigated. Pentoxifylline is known to exert a favorable influence on hemorheological disturbances in such patients. Twenty-four hour blood glucose pattern and insulin requirements were evaluated in type I and type II diabetics by the use of the artificial pancreas before and after a 14-day treatment with pentoxifylline 400 mg p.o. (Trental 400®) t.i.d. During the stabilization period before treatment with pentoxifylline, NIDDM patients required 10.1±3.8 U of insulin and the IDDM 35±13.7 U. After 2 weeks on pentoxifylline, NIDDM required only 6.3±2.8 U (p<0.05) and IDDM 28.5±9.7 U (n.s.). Average blood glucose during the 24h decreased by 15.8±3.5% in NIDDM and by 10.3±2.5% in IDDM. Moreover, a significant smoothing of glucose fluctuations during the 24h was noted in both groups. It is concluded that pentoxifylline administered concurrently to any antidiabetic type of treatment leads to better blood glucose control as well as to prevention or delay of vascular complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aikawa J. K.: Factors influencing the tissue uptake of magnesium in biologic processes. In:Aikawa J. K. (Ed.): Ch. C. Thomas, Springfield/IL, 1963.

    Google Scholar 

  2. Angelkort B., Kiesewetter H.: Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease—Scand. J. clin. Lab. Invest.41 (Suppl. 156), 185, 1981.

    Google Scholar 

  3. Angelkort B., Spürk P., Habbaba A., Mähder M.: Blood flow properties and walking performance in chronic arterial occlusive disease—Angiology36, 285, 1985.

    PubMed  CAS  Google Scholar 

  4. Barnes A. J., Locke P., Scudder P. R., Dormandy T. L., Dormandy J. A., Slack J.: Is hyperviscosity a treatable component of diabetic microcirculation disease?—Lancetii, 789, 1977.

    Article  Google Scholar 

  5. Basabe J. C., Udrisar D. P., Knopf C. F., Aparicio N.: The influence of pentoxifylline [1-(5-oxohexyl)-3,7-dimethylxanthine] (BL 191) on the insulin secretion induced by glibenclamide and by arginine/glucose in the perfused pancreas—Acta diabetol. lat.14, 263, 1977.

    Article  PubMed  CAS  Google Scholar 

  6. Blagosklonnaya Ya. V., Mamedov R., Kozlov V. V., Emanuel V. L., Judryashova M. I.: Einfluss von Trental auf die Nierenfunktion bei Patienten mit Diabetes mellitus—Probl. Endokrinol. (Moskva)28, 3, 1982.

    Google Scholar 

  7. Brancato R., Menchini U., Michelone C.: Evaluation of the action of pentoxifylline on the conjunctival microcirculation in diabetics—Pharmaceutica3 (Suppl. 1), 42, 1983.

    Google Scholar 

  8. Burr I. M., Balant L., Stauffacher W., Renold A. E.: Perfusion of rat pancreatic tissuein vitro: substrate modification of theophylline-induced biphasic insulin release—J. clin. Invest.49, 2097, 1970.

    Article  PubMed  CAS  Google Scholar 

  9. Burr I. M., Stauffacher W., Balant L., Renold A. E., Grodsky G. M.: Regulation of insulin release in perfused pancreatic tissue. In:Loubatières A., Renold A. E. (Eds): Pharmacokinetics and mode of action of oral hypoglycemic agents. Casa Editrice Il Ponte, Milano, 1969; Acta diabetol. lat.6 (Suppl. 1),580, 1969.

    Google Scholar 

  10. Butcher R. W., Sutherland E. W.: Adenosine-3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine-3′,5′-phosphate in human urine—J. biol. Chem.237, 1244, 1962.

    PubMed  CAS  Google Scholar 

  11. Cerasi E., Luft R.: The effect of an adenosine-3′,5′-monophosphate diesterase inhibitor (aminophylline) on the insulin response to glucose infusion in prediabetic and diabetic subjects—Hormone metabol. Res.1, 162, 1969.

    CAS  Google Scholar 

  12. Cerasi E., Luft R.: The effect of theophylline on the insulin response to glucose infusion in prediabetic and diabetic subjects—Diabetologia6, 39, 1970.

    Article  Google Scholar 

  13. Conte N., Federspil G., Frezzato S., Trisotto A., Scandellari C., Piemonte G.: Glucagon effect on plasma Mg concentration—Hormone metabol. Res.4, 48, 1972.

    CAS  Google Scholar 

  14. Deyhle P., Miederer S. E., Stadelmann O.: Der Einfluss von Secretion auf die durch Methylxanthine (Theophyllin) stimulierte Säure-, Elektrolyt- und Pepsinogensekretion des menschlichen Magens—Klin. Wschr.49, 1231, 1971.

    Article  PubMed  CAS  Google Scholar 

  15. Elben U., Schröer R.: Calcium complexes of xanthine derivatives: a new aspect of the mode of action of haemorheologically active drugs—Arzneimittel-Forsch.34, 3, 253, 1984.

    CAS  Google Scholar 

  16. Ensinck J. W., Stoll R. W., Gale C. C., Santen R. K., Toubery J. L., Williams R. H.: Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans—J. clin. Endocrinol.31, 153, 1970.

    CAS  Google Scholar 

  17. Grigoleit H.-G., Lehrach F.: Blutviskosität und Diabetes mellitus—Med. Mschr.27 (Suppl. 8), 353, 1973.

    PubMed  CAS  Google Scholar 

  18. Grigoleit H.-G., Lehrach F., Müller R.: Diabetic angiopathy and blood viscosity—Acta diabetol. lat.10, 1311, 1973.

    Google Scholar 

  19. Heidrich H., Schirop Th.: Blood glucose and serum insulin levels following acute and chronic pentoxifylline administration—Acta diabetol. lat.17, 15, 1980.

    Article  PubMed  CAS  Google Scholar 

  20. Heidrich H., Schirop Th., Fichte K.: Einfluss gefässaktiver Pharmaka auf den Blutzucker und das Seruminsulin—Med. Klin.72, 94, 1977.

    PubMed  CAS  Google Scholar 

  21. Heilmann E., Zimmermann B., Gruss P.: Effect of pentoxifylline in hypercoagulability in patients with polycythemia vera—IRCS med. Sci.10, 594, 1982.

    Google Scholar 

  22. Hess H., Franke I., Jauch M.: Medikamentöse Verbesserung der Fließeigenschaften des Blutes. Ein wirksames Prinzip zur Behandlung von arteriellen Durchblutungsstörungen— Fortschr. Med.91, 743, 1973.

    PubMed  CAS  Google Scholar 

  23. James D. R., Holland B. M., Hughes M. R., Jones J. G., Wardrop C. A. J.: Oxpentifylline effects on red cell deformability and oxygen availability from the blood in intermittent claudication—Clin. Hemorheol.4, 525, 1984.

    Google Scholar 

  24. Königstein R. P.: Klinische Erfahrungen mit Pentoxifyllin aus der Sicht des Diabetologen. Der praktische Arzt. Kongressband Pentoxifyllin Colloquium, Wien, 1975; p. 47–52.

  25. Lambert A. E., Jeanrenaud B., Renold A. E.: Enhancement by caffeine of glucagon-induced and tolbutamide-induced insulin release from isolated fetal pancreatic tissue—Lanceti, 819, 1967.

    Article  CAS  Google Scholar 

  26. Lambert A. E., Kanazawa Y., Halter J. B., Orci L., Rouiller C., Renold A. E.: Insulin release from fetal and newborn rat pancreasin vitro: Role of the adenylcyclase system. In:Luft R., Randle P. J. (Eds): On the pathogenesis of diabetes mellitus. Casa Editrice Il Ponte, Milano, 1970; Acta diabetol. lat.2, 229, 1970.

    Google Scholar 

  27. Larvor P., Durlach J.: Relations entre magnesium et glandes endocrines. In:Durlach J. (Ed.): First International Symposium on Magnesium Deficit in Human Pathology. J. Vittel, 1971.

  28. Lenti G., Pagano G., Angotzi G., Basetti Sani A., Diana A.: Effects of a xanthine derivative (BL 191) on insulin secretion in normal man—Europ. J. clin. Pharmacol.9, 189, 1975.

    Article  CAS  Google Scholar 

  29. Lossnitzer K., Raptis S., Grebe B., Müller R.: The influence of 3,7-dimethyl-1-(5-oxohexyl)-xanthine (pentoxifylline, BL 191) on serum calcium and magnesium levels—Arzneimittel-Forsch.23, 938, 1973.

    CAS  Google Scholar 

  30. Malaisse W., Malaisse-Lagae F.: A possible role for calcium in the stimulus-secretion coupling for glucose-induced insulin secretion. In:Luft R., Randle P. J. (Eds): On the pathogenesis of diabetes mellitus. Casa Editrice Il Ponte, Milano, 1970; Acta diabetol. lat.7 (Suppl. 1), 264, 1970.

    Google Scholar 

  31. Malaisse W. J., Malaisse-Lagae F., Mayhew D.: A possible role for the adenylcyclase system in insulin secretion—J. clin. Invest.46, 1724, 1967.

    PubMed  CAS  Google Scholar 

  32. Masowezkij A. G., Stoilov L. D., Kukaschina T. V., Tirkina T. N., Titova S. I.: The use of pentoxifylline in diabetes mellitus—Pharmatherapeutica2 (Suppl. 1), 105, 1978.

    Google Scholar 

  33. Milner R. D. G., Hales C. N.: The role of calcium and magnesium in insulin secretion from rabbit pancreas studiedin vitro—Diabetologia3, 47, 1968.

    Article  Google Scholar 

  34. Milner R. D. G., Hales C. N.: Cations and the secretion of insulin—Biochim. biophys. Acta (Amst.)150, 165, 1968.

    Article  CAS  Google Scholar 

  35. Müller R.: Pentoxifylline—A biomedical profile—J. Med.5, 307, 1979.

    Google Scholar 

  36. Müller R.: On the therapy of disturbances of blood fluidity—Angiology36, 226, 1985.

    Google Scholar 

  37. Ott E., Lechner H., Fazekas F.: Hemorheological effects of pentoxifylline on disturbed flow behaviour in patients with cerebrovascular insufficiency—Europ. Neurol.22 (Suppl. 1), 105, 1983.

    PubMed  Google Scholar 

  38. Perego M. A., Sergio G., Artale F., Giunti P., Danese G.: Haemorheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease—Curr. med. Res. Opin.10, 135, 1986.

    PubMed  CAS  Google Scholar 

  39. Petruzzi E., Bucalossi A., Corri S., Marsili A., DiNoto C.: L'uso della pentossifillina nei diabetici con claudicatio intermittens—La Ricerca Clin. Lab.13(Suppl. 3), 451, 1983.

    Google Scholar 

  40. Pfeiffer E., Beischer W., Kerner W.: The artificial endocrine pancreas in clinical research. In:Kruse-Jarres J. D., Molnar G. D. (Eds): Blood glucose monitoring. Methodology and clinical application of continuousin vivo glucose analysis. Georg Thieme Publishers, Stuttgart, 1977; Hormone metabol. Res. (Suppl. 7), 95, 1977.

    Google Scholar 

  41. Pfeiffer E., Thum Ch., Clemens A.: The artificial beta cell. A continuous control of blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion system)— Hormone metabol. Res.6, 339, 1974.

    Article  CAS  Google Scholar 

  42. Pfeiffer E., Thum Ch.,Raptis S., Beischer W., Ziegler R.: Hypoglycemia in diabetics. In:Andreani D., Lefèbvre P., Marks V. (Eds): Hypoglycemia. Georg Thieme Publishers, Stuttgart, 1976; Hormone metabol. Res. (Suppl. 6), 112, 1976.

    Google Scholar 

  43. Popendiker K., Boksay I., Bollmann V.: Zur Pharmakologie des neuen peripheren Gefässdilatators 3,7-Dimethyl-1-(5-oxohexyl)-xanthin—Arzneimittel-Forsch.21, 1160, 1971.

    CAS  Google Scholar 

  44. Raptis S.: Gastrointestinale Hormone und Insulin-und Glukagonsekretion des menschlichen Pankreas. In:Raptis S.: Enterohormone und endokrines Pankreas. Georg Thieme Verlag, 1974; p. 33.

  45. Raptis S., Escobar-Jimenez F., Maier V., Müller R., Rosenthal J.: Somatostatin and pentoxifylline modulation of insulin, glucagon and growth hormone following stimulation of arginine—Acta endocrinol. (Kbh.) (Suppl. 208), 51, 1977

    Google Scholar 

  46. Raptis S., Escobar-Jimenez F., Schlegel W., Müller R., Schröder K. E.: The influence of somatostatin on the arginine and pentoxifylline-induced insulin, glucagon and growth hormone secretion—Diabetologia12, 415, 1976; abstract #221.

    Google Scholar 

  47. Raptis S., Karaiskos K., Enzmann F., Hadjidakis D., Zoupas Ch., Souvatzoglou A., Diamantopoulos E., Moulopoulos S.: Biologic activities of biosynthetic human insulin in healthy volunteers and insulin-dependent diabetic patients monitored by the artificial endocrine pancreas—Diabetes Care4, 155, 1981.

    Article  PubMed  CAS  Google Scholar 

  48. Raptis S., Pfeiffer E. F.: Progress in oral therapy of diabetes mellitus with sulphonylureas of the second generation—Acta diabetol. lat.9, 965, 1972.

    Google Scholar 

  49. Schatz H., Hinz M., Maier V., Nierle C., Pfeiffer E. F.: Cyclic AMP and gastrointestinal hormones. Studies in isolated pancreatic islets—Acta endocrinol. (Kbh.) (Suppl. 173), 1973; Abstract #125.

  50. Schmid-Schönbein H., Volger E.: Red-cell aggregation and red-cell deformability in diabetes— Diabetes25 (Suppl. 2), 897, 1976.

    PubMed  Google Scholar 

  51. Schubotz R.: Double blind trial of pentoxifylline in diabetics with peripheral vascular disorders—Pharmatherapeutica1, 172–179, 1976.

    Google Scholar 

  52. Seiffge D., Kiesewetter H.: Effect of pentoxifylline on single red cell deformability—Klin. Wschr.59, 1271, 1981.

    Article  PubMed  CAS  Google Scholar 

  53. Serrano-Ríos M., Hawkins F. G., Escobar-Jimenez F., Rodriguez-Minon J. L.: The effect of aminophylline on insulin release induced by secretin and cholecystokinin-pancreozymin in normal humans—J. clin. Endocrinol.38, 194, 1974.

    Article  Google Scholar 

  54. Solerte S. B., Ferrari E.: Diabetic retinal vascular complications and erythrocyte filterability: results of a 2-year follow-up study with pentoxifylline—Pharmaceutica4, 341, 1985.

    CAS  Google Scholar 

  55. Strano A., Davì G., Avellone G., Novo S., Pinto A.: Double-blind cross-over study of the clinical efficacy and the haemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs—Angiology35, 439, 1984.

    Google Scholar 

  56. Sudgen M. C., Aschroft S. J. H.: Effect of phosphoenolpyruvate, other glycolytic intermediates and methylxathines on calcium uptake by a mitochondrial fraction from rat pancreatic islets—Diabetologia15, 173, 1978.

    Article  Google Scholar 

  57. Sutherland E. W., Butcher R. W., Robinson G. A., Hardman J. G.: The role of adenosine 3′,5′-monophosphate in hormone action. In:Karlson P. (Ed.): Wirkungsmechanismen der Hormone. Springer Verlag, Berlin, 1967; p. 1.

    Google Scholar 

  58. Sutherland E. W.: The role of cyclic AMP in the control of carbohydrate metabolism— Diabetes18, 197, 1969.

    Google Scholar 

  59. Thompson J. C., Reeder D. D., Buchman H. H., Becker H. D., Brandt E. M.: Effect of secretin on circulating gastrin—Ann. Surg.176, 384, 1972.

    Article  PubMed  CAS  Google Scholar 

  60. Turtle J. R., Littleton G. K., Kipnis D. M.: Stimulation of insulin secretion by theophylline— Nature (Lond.)213, 727, 1969.

    Article  Google Scholar 

  61. Volger E.: Hämorheologische Befunde beim Diabetes und ihre klinische Relevanz—Wien. med. Wschr.136 (Sonderheft), 5, 1986.

    PubMed  Google Scholar 

  62. Wilcoxon F.: Individual comparisons by ranking methods—Biometrics1, 80, 1945.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Second Department of Internal Medicine, Propaedeutic, Athens University, Evangelismos Hospital, P.O. Box 14127, 115 10, Athens, Greece

    Sotos Raptis, Asimina Mitrakou, Dimitrios Hadjidakis, Emmanuel Diamantopoulos, Costas Anastasiou, Artemis Fountas & Roland Müller

Authors
  1. Sotos Raptis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asimina Mitrakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dimitrios Hadjidakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuel Diamantopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Costas Anastasiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Artemis Fountas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roland Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dedicated to Prof. Dr. med. h.c. Ernst F. Pfeiffer on the occasion of his 65th birthday anniversary.

This work was supported by grants from the Social Ministry, Athens, Greece; Department of Internal Medicine I, University of Ulm, FRG;Deutsche Forschungsgemeinschaft SFB87 Endokrinologie, Ulm, FRG; the Alexander Onassis Foundation, Vaduz, Liechtenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raptis, S., Mitrakou, A., Hadjidakis, D. et al. 24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas. Acta diabet. lat 24, 181–192 (1987). https://doi.org/10.1007/BF02732036

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02732036

Key-words

Search

Navigation